Division of Hematoloy-Oncology, Genomic Medicine Research Core Lab, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan, ROC.
Anticancer Res. 2012 Apr;32(4):1259-65.
Cancer genomic signatures may vary using different platforms. We compared the differential gene expression in non-small cell lung cancer (NSCLC) between two platforms in order to find the most relevant genomic signatures of tumor recurrence.
We analyzed gene expression in frozen lung cancer tissue from 59 selected patients who had undergone surgical resection of NSCLC. These patients were divided into two groups: group R, patients who had a tumor recurrence within four years, n=37; group NR, patients who remained disease-free four years following initial surgery, n=22. Each RNA sample was assayed twice using both Affymetrix and Illumina GeneChip. Data were analyzed by principal component analysis and leave-one-out cross-validation.
Using the same filtering criteria, 13 genes that were differentially expressed between R and NR were identified by Affymetrix, while 21 genes were identified by Illumina GeneChip. In common, a total of six genes were detected by both systems. Using univariate analysis, four (lipocalin 2, LCN2; parathyroid hormone-like hormone, PTHLH; ras-related protein Rab-38, RAB38; and four jointed box 1, FJX1) of these six genes were associated with survival. A risk score of survival was calculated according to the four-gene expression. There was a significant difference in overall survival between low- and high-risk groups.
A four-gene signature is associated with survival among patients with early-stage NSCLC. Further validation of these findings is warranted.
癌症基因组特征可能因使用不同的平台而有所不同。我们比较了两个平台之间非小细胞肺癌（NSCLC）的差异基因表达，以寻找与肿瘤复发最相关的基因组特征。
我们分析了 59 名接受 NSCLC 手术切除的选定患者冷冻肺癌组织中的基因表达。这些患者分为两组：R 组，肿瘤在四年内复发的患者，n=37；NR 组，初始手术后四年内无疾病的患者，n=22。每个 RNA 样本均使用 Affymetrix 和 Illumina GeneChip 进行两次检测。通过主成分分析和留一交叉验证进行数据分析。
使用相同的过滤标准，Affymetrix 鉴定出 13 个在 R 和 NR 之间差异表达的基因，而 Illumina GeneChip 鉴定出 21 个基因。共有 6 个基因被两个系统同时检测到。使用单变量分析，其中四个基因（载脂蛋白 2、LCN2；甲状旁腺激素样激素、PTHLH；Ras 相关蛋白 Rab-38、RAB38；和四个关节盒 1、FJX1）与生存相关。根据四个基因的表达计算了生存风险评分。低风险组和高风险组之间的总生存率存在显著差异。
早期 NSCLC 患者的四基因特征与生存相关。需要进一步验证这些发现。
